$0.82
+0.04 (+4.46%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LGVN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 with posted results
Held by 3 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 7.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.NCT04925024Change in right ventricular ejection fraction (RVEF)Randomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Biological: Lomecel-B medicinal signaling cells | Hypoplastic Left Heart Syndrome | 40 | 2026-06-30 | 2025-06-25 |
| Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)NCT03525418Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.Randomized · Double-masked · Treatment | Phase 1/2 | Unknown status | Biological: Longeveron Mesenchymal Stem Cells | HLHS | 10 | 2024-06-30 | 2023-10-04 |
| Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)NCT04629105Incidence of Treatment-Emergent Serious Adverse EventsRandomized · Double-masked · Treatment | Phase 1 | Unknown status | Biological: Longeveron Mesenchymal Stem Cells (LMSCs) · Other: Placebo | ARDS, Human, Covid19 | 70 | Jun 2024 | 2024-02-20 |
| Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA TrialNCT02587572Endothelial function: Changes in endothelial function as assessed by the following:Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor has made decision not to conduct this clinical trial. | Biological: Peripheral Intravenous (IV) infusion of LMSCs | Metabolic Disease, Endothelial Dysfunction | 0 | Dec 2023 | 2023-02-16 |
| Lomecel-B Effects on Alzheimer's DiseaseNCT05233774Primary Endpoint 1: Safety - SAEs and AEsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Allogeneic MSC · Other: Placebo | Mild Alzheimer's Disease | 50 | 2023-09-29actual | 2024-02-20 |
| Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging FrailtyNCT02982915The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Biological: Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine | Aging Frailty | 62 | Sep 2021actual | 2022-11-04 |
| Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging FrailtyNCT03169231Change from baseline in 6 Minute Walk Test (6MWT) compared to placeboRandomized · Triple-masked · Treatment | Phase 2 | Completed | Biological: Longeveron Mesenchymal Stem Cells (LMSCs) · Other: Placebo | Aging Frailty | 150 | 2021-09-30actual | 2022-03-07 |
| Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's DiseaseNCT02600130To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: Longeveron Mesenchymal Stem Cells, Placebo | Alzheimer's Disease | 33 | Sep 2020actual | 2021-12-14 |
| AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS DeliveryNCT02065245results2021-04-27Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Frailty | 65 | 2019-10-02actual | 2021-07-14 |
| Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart SyndromeNCT02398604Monitor major adverse cardiac eventsRandomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study was closed due to Sponsor switched to Longeveron. New Identifier is NTC03525418 | Drug: Allo-hMSCs, Placebo | Hypoplastic Left Heart Syndrome | 5 | Mar 2019actual | 2021-07-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19